India immune oncology drugs market analysis | Coherent Market Insights

1
Coherent Marketing Insights

• Market Research Business Consulting Services

• https//www.coherentmarketinsights.com/

• Covid-19 Impact Tracker

2

• INDIA IMMUNE-ONCOLOGY DRUGS MARKET ANALYSIS
• India Immune-Oncology Drugs Market, By Drug Type
  (Immune Checkpoint Inhibitors, Monoclonal
  Antibodies, and Cancer Vaccines) and By Cancer
  Type (Lung Cancer, Blood Cancer, Breast Cancer,
  Ovarian Cancer, Cervical Cancer, Colorectal
  Cancer, Stomach Cancer, Head Neck Cancer, and
  Others) - Size, Share, Outlook, and Opportunity
  Analysis, 2018 2026

3

• Immuno-Oncology refers to the use of bodys
  natural defenses to fight disease. It works by
  stimulating the immune system instead of fighting
  the tumors, avoiding disturbance in functionality
  of healthy cells. Immuno-oncology drugs
  facilitates long-term response against cancer by
  providing long-lasting memory to the immune
  system. Immuno-Oncology drugs works against a
  wide variety of cancers, which include non-small
  cell lung cancer, acute myeloid leukemia,
  lymphoma, multiple myeloma, breast cancer, and
  others. Immuno-oncology uses different types of
  cell-based immune therapies such as monoclonal
  antibodies, immune checkpoint inhibitors,
  cytokine-based immunotherapy, cancer vaccines,
  and other therapies. Commercially available
  immune-oncology therapies include Iplimumab,
  Nivolumab, Rituximab, Blinatumomab, Proleukin,
  Gardasil, and Kymriah.

4

• Market Dynamics
• Increasing prevalence of cancer in India is
  expected to drive India Immuno-Oncology Drugs
  market growth. For instance, according to
  National Cancer Registry Programme (NCRP), India,
  one woman dies of cervical cancer every 8 minutes
  in India. For every 2 women newly diagnosed with
  breast cancer, one woman dies of it in India.
  Furthermore, as many as 2,500 persons die every
  day due to tobacco-related diseases in India.
  Tobacco (smoked and smokeless) use accounted for
  around 317,928 deaths in men and women in 2018.
• However, factors such as high-cost associated
  with immuno-oncology therapies makes it
  unaffordable for population in the low and
  middle-income class, to opt for these therapies,
  thus restraining growth of the market. For
  instance, Keytruda (Pembrolizumab), a monoclonal
  antibody for the treatment of various types of
  cancer costs around US 2,250 for a vial of 50
  mg. Moreover, according to the World Health
  Organization (WHO), in February 2018, around 70
  of deaths from cancer occur in low and
  middle-income countries. This can be attributed
  to high-prices of oncology therapies, which
  cannot be afforded by patients with low incomes.

5

• Key features of the study
• This report provides in-depth analysis of the
  India immuno-oncology drugs market, market size
  (US Mn), and Compound Annual Growth Rate (CAGR
  ()) for the forecast period 2018 2026,
  considering 2017 as the base year
• It elucidates potential revenue opportunity
  across different segments and explains attractive
  investment proposition matrix for this market
• This study also provides key insights about
  market drivers, restraints, opportunities, new
  product launches or approval, market trends,
  regional outlook, and competitive strategies
  adopted by leading players
• It profiles key players in the India
  immuno-oncology drugs market based on the
  following parameters company overview,
  financial performance, product portfolio,
  geographical presence, distribution strategies,
  key developments, and strategies
• Key players covered as a part of this study
  include Amgen, Inc., F. Hoffmann-La Roche AG,
  Intas Pharmaceuticals Ltd., AstraZeneca plc,
  Mylan N.V., Dr. Reddy's Laboratories, Bristol -
  Myers Squibb, Merck Co., Inc.,
  BIOCAD-Biotechnology company, Reliance Life
  Sciences, Biocon Limited and Hetero Drugs
  Limited.
• Insights from this report would allow marketers
  and management authorities of companies to make
  informed decision with respect to their future
  product launch, governmental initiatives,
  technological up-gradation, market expansion, and
  marketing tactics

6
Detailed Segmentation

• India Immuno-Oncology Drugs Market, By Drug Type
• Immune Checkpoint Inhibitors
• Nivolumab (Opdivo)
• Atezolimumab (Tecentriq)
• Pembrolizumab (Keytruda)
• Durvalumab (Imfinzi)
• Monoclonal Antibodies
• Rituximab (Rituxan)
• Trastazumab (Herceptin)
• Bevacizumab (Avastin)
• Nimotuzumab (Biomab EGFR)
• Pertuzumab (Perjeta)
• Ado-Trastuzumab Emtansine (Kadcyla)

7
India Immuno-Oncology Drugs Market, By Cancer
Type

• Lung Cancer
• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Colorectal Cancer
• Stomach Cancer
• Head Neck Cancer
• Others
• Company Profiles
• Amgen, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies

8

• Hoffmann-La Roche AG
• Intas Pharmaceuticals Ltd.
• AstraZeneca plc
• Mylan N.V.
• Reddy's Laboratories
• Bristol - Myers Squibb
• Merck Co., Inc.
• BIOCAD-Biotechnology company
• Reliance Life Sciences
• Biocon Limited
• Hetero Drugs Limited

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Referance https//www.coherentmarketinsights.com/
  market-insight/india-immune-oncology-drugs-market-
  2631

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions. We are headquartered
  in India, having office at global financial
  capital in the U.S. Our client base includes
  players from across all business verticals in
  over 150 countries worldwide.
• What We ProvideCustomized Market Research
  AnalysisIndustry Analysis ServicesBusiness
  Consulting ServicesLong Term Engagement
  ModelCountry Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt. LTD.Coherent
  Market Insights 1001 4th Ave, 3200 Seattle, WA
  98154, U.S.Phone [phone]
• Email sales_at_coherentmarketinsights.com

12
Thank You

• Kindly Follow CMI Social Media Profiles for the
  latest Company Updates.
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/